{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:04:17Z","timestamp":1787879057162,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40256-022-00526-9","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:16:09Z","timestamp":1648613769000},"page":"445-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1007","volume":"22","author":[{"given":"Mark H.","family":"Rozenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Bhambri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"22","key":"526_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"526_CR2","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"issue":"10","key":"526_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"526_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2(2): e000098.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"526_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222-8 e1.","journal-title":"Am Heart J"},{"key":"526_CR6","doi-asserted-by":"publisher","unstructured":"Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2021. https:\/\/doi.org\/10.1007\/s10741-021-10080-2.","DOI":"10.1007\/s10741-021-10080-2"},{"issue":"12","key":"526_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004873","volume":"11","author":"SL Jackson","year":"2018","unstructured":"Jackson SL, Tong X, King RJ, Loustalot F, Hong Y, Ritchey MD. National burden of heart failure events in the United States, 2006 to 2014. Circ Heart Fail. 2018;11(12): e004873.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"526_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","volume":"38","author":"M Urbich","year":"2020","unstructured":"Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A systematic review of medical costs associated with heart failure in the USA (2014\u20132020). Pharmacoeconomics. 2020;38(11):1219\u201336.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"526_CR9","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.cardfail.2020.09.362","volume":"26","author":"MV Llonch","year":"2020","unstructured":"Llonch MV, Ortiz-Perez JT, Reddy SR, Chang E, Tarbox MH, Pollock MR, et al. Cardiovascular disease burden prior to hereditary transthyretin amyloidosis diagnosis. J Card Fail. 2020;26(10):S125\u20136.","journal-title":"J Card Fail"},{"issue":"11","key":"526_CR10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.amjcard.2019.08.045","volume":"124","author":"BW Sperry","year":"2019","unstructured":"Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA. Increasing rate of hospital admissions in patients with amyloidosis (from the national inpatient sample). Am J Cardiol. 2019;124(11):1765\u20139.","journal-title":"Am J Cardiol"},{"issue":"11","key":"526_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"304","key":"526_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","volume":"1","author":"B Ladefoged","year":"2020","unstructured":"Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis\u2014a clinical challenge. Int J Cardiol. 2020;1(304):138\u201343.","journal-title":"Int J Cardiol"},{"issue":"11","key":"526_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2217\/cer-2021-0071","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Young R, Doornewaard AV, et al. Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. J Comp Eff Res. 2021;10(11):927\u201338.","journal-title":"J Comp Eff Res."},{"issue":"1","key":"526_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141\u201359.","journal-title":"Cardiol Ther."},{"issue":"1","key":"526_CR15","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7\u201322.","journal-title":"Circulation"},{"issue":"4","key":"526_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","volume":"3","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, et al. Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. JACC CardioOncol. 2021;3(4):537\u201346.","journal-title":"JACC CardioOncol."},{"key":"526_CR17","doi-asserted-by":"crossref","unstructured":"Rozenbaum MH, Ionescu I, Clausen M, Lopez M, Sultan MB, Attal S. Baseline characteristics of patients with transthyretin amyloid cardiomyopathy enrolled in a tafamidis expanded access program. Eur Heart J. 2021;42(Supplement_1):ehab724.1799","DOI":"10.1093\/eurheartj\/ehab724.1799"},{"issue":"2","key":"526_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail. 2021;9(2):115\u201323.","journal-title":"JACC Heart Fail."},{"issue":"6","key":"526_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","volume":"10","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A et al. Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. 2017;10(6):e003815.","journal-title":"Circ Heart Fail."},{"issue":"5","key":"526_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40256-021-00464-y","volume":"21","author":"C Vong","year":"2021","unstructured":"Vong C, Boucher M, Riley S, Harnisch LO. Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Am J Cardiovasc Drugs. 2021;21(5):535\u201343.","journal-title":"Am J Cardiovasc Drugs"},{"key":"526_CR21","doi-asserted-by":"crossref","unstructured":"Li H, Rozenbaum MH, Casey M, Sultan MB. Estimating treatment effect of tafamidis on hospitalization in NYHA class III ATTR-CM patients in the presence of death using principal stratification. Eur Heart J. 2021;42(Supplement_1):ehab724.0829.","DOI":"10.1093\/eurheartj\/ehab724.0829"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00526-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00526-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00526-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T04:34:06Z","timestamp":1657254846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00526-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00526-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"18 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was financially supported by Pfizer Inc., who also funded the journal\u2019s Open Access fee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mark Rozenbaum and Rahul Bhambri are employees of Pfizer and hold Pfizer stock and\/or stock options. Editorial\/medical writing support and data analysis were provided by Diana Tran at EVERSANA and was funded by Pfizer Inc. Jose Nativi-Nicolau received funding for clinical trials from Pfizer, Akcea, and Eidos and Educational Grants from Pfizer and has been a consultant for Pfizer, Eidos, Akcea, and Alnylam.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. MHR and DT designed the study. DT conducted the analyses and drafted the manuscript. All authors critically reviewed the manuscript for intellectual content and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}